R. Hu

发表

Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker

Peiyun Liao, Binyan Xu, Yingqi Qiu, 2022, BMC Genomic Data.

Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker

Peiyun Liao, Binyan Xu, Yingqi Qiu, 2022 .

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Chujun Li, Yuhua Li, Yingqi Qiu, 2021, Biomarker research.

Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker

Y. Qiu, Pei-Yin Liao, Hao Wang, 2022 .

CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?

Qianming Du, Hui Wang, Chao Liu, 2023, Frontiers in Pharmacology.

N6-methyladenosine RNA modifications: a potential therapeutic target for AML

Yuhua Li, Honghao Zhang, Peiyun Liao, 2023, Annals of hematology.

Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia

Hao Wang, Xiaoling Xie, Ning Chang, 2023, Cell death & disease.

Editorial: Crosstalk between cancer-associated fibroblasts and tumor cells in the tumor microenvironment: an emerging target of anti-cancer immunotherapy

Qianming Du, R. Sun, B. Kong, 2023, Frontiers in pharmacology.

Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma.

Yanjie He, Xiaoling Xie, Meifang Li, 2024, Cancer letters.